This study aimed to investigate the effects of polymorphisms of the flavin-containing mono-oxygenase 3 (FMO3) and flavin-containing mono-oxygenase 6 (FMO6) genes on the pharmacokinetics of sulindac sulfide, the active metabolite of sulindac, in patients with preterm labor. Ten single-nucleotide polymorphisms (SNPs) were genotyped, and plasma sulindac sulfide concentrations were measured at 0, 1.5, 4, and 10 hours after drug administration. The area under the curve from time 0 to the last sampling time point (AUC last ) for sulindac sulfide was obtained. The AUC last of sulindac sulfide was significantly higher in patients with variant-type homozygotes of FMO3 (rs909530) than those with ancestral alleles or heterozygotes. FMO3 (rs2266780) was in complete linkage disequilibrium with FMO6 (rs7885012), and there was marginal significance between the genotypes (P = 0.049). From multiple linear regression models, FMO3 (rs909530) was found to have significant influence on the AUC last of sulindac sulfide after adjusting for gestational age, weight, and all studied SNPs. The predictive contribution of rs909530 to the variability of sulindac sulfide AUC last was 27.0%. In conclusion, the results of this study could help clinicians predict the efficacies and side effects of sulindac in the development of individualized treatment of patients with preterm labor.
Introduction
Sulindac is a prostaglandin synthetase inhibitor (Nuki, 1983) . As prostaglandin increase is observed in both term and preterm labor, prostaglandin inhibitors have been used as tocolytic agents (Karim, 1968) . Sulindac contains a chiral sulfoxide moiety and is administered clinically as a racemate. It is an inactive prodrug and is reduced to a pharmacologically active metabolite, sulindac sulfide. Sulindac is also oxidized to an inactive metabolite, sulindac sulfone. The sulfide form is inactivated by flavin-containing mono-oxygenase 3 (FMO3), and the (S)-and (R)-sulindac sulfoxides are also oxidized to sulindac sulfone by FMO3 (Hamman et al., 2000; Hisamuddin and Yang, 2007) .
Several studies showed that FMO3 gene polymorphisms could result in interindividual and interethnic differences in FMO3 activity (Cashman and Zhang, 2002; Hernandez et al., 2003) . The polymorphisms could result in differences in the pharmacokinetics and responses of drugs that are metabolized by FMO3, including sulindac. It was reported that genetic polymorphisms of FMO3 could affect clinical outcomes in patients with sulindac therapy due to adenomatous polypsis. The studied end points were pharmacodynamic responses such as polyposis prevention and regression (Hisamuddin et al., 2004 (Hisamuddin et al., , 2005 . However, there has been no study conducted on the effects of FMO3 genotypes on the blood concentrations of an active sulindac metabolite in clinical settings.
It has been reported that flavin-containing mono-oxygenase 6 (FMO6) has significant sequence homology with FMO3 Hernandez et al., 2004; Hisamuddin and Yang, 2007) . However, unlike FMO3, the study of the effects of FMO6 polymorphisms on drug therapy has been rarely conducted. Therefore, in this study, we examined the effects of FMO3 and FMO6 gene polymorphisms on the blood exposure of sulindac sulfide in pregnant women with preterm labor.
Materials and Methods
Study Patients and Data Collection. Forty-one patients diagnosed with preterm labor between 16 and 37 weeks' gestation at Ewha Womans University Mokdong Hospital were enrolled in this study from March 2010 to January 2013. Patients were eligible for the study if they met the following criteria: preterm labor with an intact membrane, gestational age of 16-37 weeks, $18 years of age, uterine contractions with a frequency of 3 per 10 minutes with cervical change, and provision of written informed consent. Exclusion criteria were congenital anomaly, rupture of membranes, major vaginal bleeding, severe pre-eclampsia, fetal/placental/amniotic abnormalities, fetal distress, and women whose continuation of pregnancy would be dangerous for them.
Patients were given a 200 mg sulindac (Imbaron; Sam Jin Pharm., Seoul, Korea) by the oral route twice per day. Blood samples were collected at 0, 1.5, 4, and 10 hours following the first dosing and stored at 270°C prior to analysis.
The data collected included maternal age, body weight, gestational age, type of gestation, cervical dilation, modified Bishop Score, and medications used concomitantly with sulindac.
This prospective study was approved by the Ethics Committee of the Ewha Womans University Mokdong Hospital Institutional Review Board. All patients gave written informed consent for participation.
Materials. Sulindac sulfide (sulfide) and indomethacin [internal standard (IS)] were purchased from Sigma-Aldrich (St. Louis, MO). Potassium phosphate monobasic was purchased from Samchun Pure Chemical Co. (Pyungtaek, Gyeonggi-do, Korea) . Acetonitrile high-performance liquid chromatography (HPLC) grade was purchased from J. T. Baker (Phillipsburg, NJ). Other reagents were of analytical grade.
Genotyping Methods. Genomic DNA from the patients was isolated from EDTA-blood samples using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany), according to the protocol of the manufacturer. Genotyping of 10 single-nucleotide polymorphisms (SNPs) was conducted using sequencing or a SNaPShot assay: rs2266780 (A.G, Glu308Gly), rs1736557 (G.A, Val257Met), rs2266782 (G.A, Glu158Lys), and rs909530 (C.T, Asn285Asn) of FMO3, and rs7885012 (A.G), rs2281004 (A.G), rs1920150 (T.C), rs17565766 (G.A), rs1795243 (C.A), and rs1795242 (A.C) of FMO6 genes. The SNPs were selected on previously published data from gene-candidate approaches and Tag SNPs (Koukouritaki et al., 2005) .
HPLC Analysis. Samples were analyzed by HPLC (Reid et al., 2008) . The HPLC system (Shimadzu, Kyoto, Japan) consisted of a pump (CBM-20A) with a UV detector (SPD-20A) and an autosampler (SIL-20A). The UV wavelength was 340 nm, with a flow rate of 1.0 mL/min. Sulindac sulfide concentrations were determined using Zorbax SB-CN columns (4.6 Â 150 mm, 5 mm; Agilent Technologies, Palo Alto, CA) with a mobile phase composed of 50 mmol/L potassium phosphate (pH 3):acetonitrile (55:45, v/v %). The injection volume was 20 mL.
Preparation of Standard and Sample Plasma. Stock solutions of sulindac sulfide and IS were prepared in acetonitrile at a concentration of 1 mg/mL. The stock solutions were diluted with acetonitrile-water (75:25, v/v%) to obtain working solutions. For the standard curve, 25 mL of plasma was spiked with 5 mL of the working solutions to make the final sulindac sulfide (0.3, 0.5, 1, 3, and 5 mg/mL) concentrations. Twenty-five microliters of IS (1 mg/mL) was added to 30 mL of standard and patient plasma. The samples were mixed for 15 seconds, followed by the addition of 0.25 mL of acetonitrile to each tube to precipitate the proteins, and then vortex mixed for 2 minutes and centrifuged for 10 minutes. The supernatant was concentrated to dryness by a centrifugal evaporator (EZ-2 plus; Genevac, Ipswich, Sulffolk, UK). The residue was reconstituted with 200 mL of acetonitrile-water (75:25, v/v%), and 20 mL was injected onto the HPLC column.
Method Validation. Standards at concentrations of 0.3, 0.5, 1, 1.5, 3, and 5 mg/mL for sulindac sulfide were assayed, as mentioned above. The calibration curve was constructed based on the peak area ratio of the drug and IS. A linear relationship was obtained (r 2 = 0.9997). Intraday precision was defined by the percentage of the relative standard deviation of five standard sets at six different concentrations analyzed on the same day. The interday precision was estimated from the analysis of the six standards on 5 separate days during the method validation. The intra-and interday precisions of sulindac sulfide were in the ranges of 2.9;10.6 and 6.3;9.0%, respectively, which was acceptable for all the quality control samples (Karnes et al., 1991) .
Pharmacokinetic Analysis. The area under the curve from time 0 to the last sampling time point (AUC last ) for sulindac sulfide was calculated using WinNonlin (version 2.1; Pharsight Corporation, Mountain View, CA).
Statistical Analysis. All analyses were performed with the Package for Social Sciences Version 12.0 for Windows (SPSS 12.0K; SPSS INC., Chicago, IL). A P value , 0.05 was considered to be statistically significant. The MannWhitney U test was used to evaluate the significance of differences in pharmacokinetic parameters between the two genotypic groups.
Results
The mean age of the study patients was 32.4 6 4.4 years, with a range of 20;41 years. The mean body weight was 58.8 6 9.2 kg, and the mean gestational age was 27.1 6 4.2 weeks. The mean modified Bishop score was 1.05 6 1.34. Five patients were multiple pregnancies (all were twins) among the pregnant women whose gestational type was identified. The mean contraction frequency was 8.9 6 6.4 per 30 minutes, and the mean cervical dilation was 1.07 6 0.91 cm. Ritodrine and magnesium sulfate were administered with sulindac concomitantly to 19 (46.3%) and 3 (7.3%) patients of 41, respectively. Among the characteristics, body weight and gestational age were significant factors for the sulindac sulfide AUC last (Table 1) . The sulindac sulfide AUC last values increased in patients with a low body weight and gestational age.
The genotypes and minor allele frequencies of the study SNPs are shown in Table 2 . The observed frequencies were consistent with the Hardy-Weinberg equilibrium in all SNPs except for rs1795242 of the FMO6 gene. The AUC last of sulindac sulfide, the active metabolite of sulindac, was significantly higher in patients with variant-type homozygotes of FMO3 (rs909530) than those with ancestral alleles or heterozygotes.
A complete linkage disequilibrium was found between FMO3 rs2266780 and FMO6 rs17565766. In rs2266780, the AUC last of sulindac sulfide was higher in patients with heterozygotes compared with those with ancestral alleles (marginal significance, P = 0.049).
From multiple linear regression models, only FMO3 (rs909530) was found to have significant influence on the AUC last of sulindac sulfide after adjusting for gestational age, weight, and all studied SNPs. The predictive contribution of rs909530 to the variability of sulindac sulfide AUC last was 27.0% (parameter estimate = 2.9611, P , 0.01).
Discussion
This study is the first one to examine how different genotypes of sulindac-metabolizing enzymes including FMO3 and FMO6 affect the pharmacokinetic characteristics of sulindac sulfide in the clinical setting. Sulindac is a prodrug that is reduced to sulindac sulfide, its active form. The active form is oxidized to sulindac sulfoxide and, subsequently, sulfone, by FMO3. In this study, the pharmacokinetic characteristics of sulindac sulfide were evaluated because they could be a marker of drug effectiveness as well as a good indicator of the activity of sulidac-metabolizing enzymes such as FMO3 and FMO6.
FMO3 enzymes, which are abundant in the adult liver, catalyze NADPH-dependent oxygenation of a variety of nucleophilic heteroatomcontaining compounds, including many drugs, pesticides, and other foreign compounds (Hines et al., 1994) . Several studies revealed the genotype-phenotype correlation of several FMO3 mutations (Zschocke et al., 1999; Cashman et al., 2000; Stormer et al., 2000) . Those studies mainly focused on three SNPs, which were E158K (rs2266782), E308G (rs2266780), and V257M (rs1736557). The studies reported that the polymorphisms of E158K and E308G showed decreased FMO3 catalytic activity, whereas V257M did not reveal any influence on enzyme activity (Cashman et al., 2000; Dolphin et al., 2000) .
It has been reported that there is a cis-linkage between K158 and G308 variants. The power (%) to predict prevalence of one variant by measuring another variant in the K158 and G308 variants was revealed to vary depending on the ethnic group: non-African subjects (12.0;38.3) showed a different power from African subjects (1.3%) (Mao et al., 2009) . In this study, the power was calculated to be 32.5%, which was relatively high. Therefore, it was expected that these polymorphisms could affect the amount or sensitivity of the FMO3 enzyme in our population. In addition, it was found that the reduced enzyme activity varied depending on the substrate (Cashman et al., 2000; Park et al., 2002; Lattard et al., 2003) . In our study, only rs2266780 showed marginal significance (P = 0.049). Patients with polymorphisms of E308G showed decreased metabolism of sulindac sulfide compared with those with ancestral alleles.
FMO6 has been poorly investigated, and the effects of SNPs have yet to be defined. In this study, the effects of FMO6 gene polymorphisms on the AUC last of sulindac sulfide were examined using tag SNPs. Among the studied tag SNPs, only rs1565766 showed statistical significance among the genotypes; rs1565766 was in complete linkage disequilibrium with FMO3 SNP (rs2266780) in our study population, suggesting that either of the two SNPs or both together affect the AUC last of sulindac sulfide. Considering that the FMO6 gene of humans is a pseudogene, the polymorphisms of the FMO6 gene would not affect FMO6 protein function.
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at ASPET Journals on June 23, 2017 dmd.aspetjournals.org FMO3 rs909530 was identified within exon sequences (Koukouritaki et al., 2005) . From multivariate analysis, rs909530 showed significant effects on the AUC last of sulindac sulfide. This was attributable to the decreased FMO3 activity in patients with mutant alleles. Recent study also showed that rs909530 among studied polymorphisms was significantly associated with clinical endpoints such as febrile neutropenia, reduced absolute neutrophil count, and hemoglobin reduction in patients on docetaxel (Awada et al., 2013) . It is a synonymous SNP, which is not expected to change the catalytic activity of sulindac sulfide. The effect of synonymous SNP on sulindac metabolism in the FMO3 gene in this study was possibly attributable to the linkage disequilibrium with other SNPs, which have functional activities (Kimchi-Sarfaty et al., 2007) . In addition, a recent study showed that synonymous coding SNPs can affect the translation rate of mRNA, resulting in changes in the amount of protein produced and the posttranslational modification of the protein (Zhang et al., 2010) . Another possibility is that it interferes with an exon-splicing enhancer, affecting RNA processing (Koukouritaki et al., 2005) . Among pharmacokinetic parameters, only the AUC last value was obtained for the blood exposure of sulindac sulfide, due to the drug administration protocol and patient compliance in this study. Sulindac was administered twice daily; therefore, the last sampling time had to be within 12 hours after drug administration. In this study, blood samples were collected at 0, 1.5, 4, and 10 hours after the first dosing to improve patient compliance. Because the final sampling time was not enough to get elimination rate constants in several patients, the AUC inf , k e , Cl, and t 1/2 values were not calculated. However, pregnant women with preterm labor need to have rapid arrest; therefore, the effects as early as within 10 hours are practically important.
Along with the sampling time problems, there are other possible limitations of this study. Sulindac is not the first choice to treat pregnant women with preterm labor because of its oral dosing. In our institute, sulindac is used as an add-on therapy in patients who are not treated effectively with ritodrine injection. Thus, it was not possible to obtain the pharmacodynamic phenotype by sulindac therapy alone. The pharmacokinetic results in this study were valuable, though, because it has been reported that concomitant drugs such as ritodrine and magnesium sulfate do not have pharmacokinetic interactions with sulindac, and they are not substrates of FMO3 or FMO6 (Armstron et al., 2009) .
To elucidate the effects of genotypes of the sulindac-metabolizing enzymes on sulindac metabolism, further study using large populations is required. Nevertheless, this study is valuable as the first in vivo study to demonstrate the genetic polymorphisms of the FMO3 and FMO6 genes on the pharmacokinetics of sulindac sulfide in pregnant women with preterm labor. Differences in the bioavailability of the active sulindac metabolite, sulindac sulfide, are attributable to the genetic polymorphisms of FMO3 and FMO6 in subjects with preterm labor. Especially, the contribution of rs909530 of FMO3 on sulindac exposure for 10 hours after drug administration was 27%, which was almost the same as that of vitamin K epoxide reductase complex subunit 1 genotypes on warfarin stable doses in a Korean population (Lee et al., 2012) . The results of this study could help clinicians predict efficacies and side effects of sulindac in the development of individualized treatment plans for patients with preterm labor.
